Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation.
about
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation updateGenetics of Parkinson's diseaseGenetically engineered mouse models of Parkinson's diseaseThe genetics and neuropathology of Parkinson's diseaseGenetics of Parkinson's disease - a clinical perspectiveGenetics in Parkinson disease: Mendelian versus non-Mendelian inheritanceAlpha-synuclein spreading in Parkinson's diseaseHuntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study.α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathyGlial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons.Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval.Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death.Familial dementia with Lewy bodies with an atypical clinical presentation.Familial occurrence of dementia with Lewy bodies.Diagnosis and treatment of Parkinson disease: molecules to medicineGenetic neuropathology of Parkinson's disease.Genotype-phenotype correlation: familial Parkinson disease.E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairmentCognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.Clinical approach to Parkinson's disease: features, diagnosis, and principles of management.Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.Expanding the prion disease repertoire.Genetic causes of Parkinson's disease in the Maltese: a study of selected mutations in LRRK2, MTHFR, QDPR and SPRNeurodegenerative disorders: Parkinson's disease and Huntington's diseaseMacroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α-synuclein mutationParkinson's disease: the genetics of a heterogeneous disorder.Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease.α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?Protein expression in a Drosophila model of Parkinson's disease.Proteomics in animal models of Alzheimer's and Parkinson's diseases.Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease.Targeting the progression of Parkinson's disease.Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.Molecular mechanisms of alpha-synuclein neurodegeneration.Genomic investigation of alpha-synuclein multiplication and parkinsonism.Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps.
P2860
Q22252904-F55B6F51-A652-407A-9AA6-C5728515275AQ26827825-54586C03-AF64-4B0F-8B14-B0447DC56E12Q26852964-F189CEF0-D030-47A4-901D-CA084CE0E36DQ26859945-2D279839-2569-4D06-B7E8-65D3EF936D20Q27022109-9A467839-0B4D-41D5-B4C0-F85B4C0E148BQ28077356-AD1FED9F-7ED1-40D7-B638-AE3F8193492CQ28082548-C7442E4A-D581-41E2-878B-BE94F5381BB1Q30438950-B3CC881F-D34E-4C5D-8369-C4DACC9390DCQ30471591-F18A2F8D-0B17-48D8-A7F5-3F8595875112Q30662442-58A334FB-36D5-48C9-B258-16F8E21687FFQ30991616-D01D49B5-62C6-4BD6-BE60-A935823D3E62Q33616462-FBC02694-5008-4199-A2D9-68A07CD8BE65Q33701172-8D06DD29-2ABB-4CBB-A9DA-2ADD94B41F5DQ33909482-892E9FE9-39F0-4CE9-8069-0D90D2F8A891Q33942173-63AEA92F-C10A-4BF0-AEA2-A3D3921E0302Q34043163-3A15DC0A-6616-466F-B11B-33DBEE7C5750Q34696605-56823B06-682C-4D38-A239-1B9486D58B5AQ34696623-1997D7AA-8B56-4D1E-94FC-D7F60421340CQ34698876-1E0E1597-A1EC-43CD-AF6B-28E20AF25066Q34825312-20376612-6336-4ABF-89EB-1AFFACCA7EF6Q35117826-34A8A531-5376-4CC0-B74A-1BC9ACBEE922Q35266392-28478D44-398F-4B4B-9A2C-9D9A69FD284FQ35988441-6E532461-D650-479A-BEBE-5FD0C9B79CC5Q36009241-E831A7F3-F77F-4F56-BE94-CAEE119CC48BQ36011221-0B6B6711-38C4-4576-AD5F-10046B7A52FBQ36102969-DB0C99A4-DC92-4EDE-AF16-CCC913030F3CQ36128958-DCD6F351-0A4E-4C6F-9C2A-B621A26FACD2Q36198011-0A66926F-A90E-4BC5-9273-4A5C9B3172A6Q36424977-5A6B2F17-8A3E-47F1-BEAA-FD90EBD0E055Q36516918-08DA5B08-E540-4866-8CD5-B4AB8803CB8AQ36804685-78FADFB7-BCDA-40AA-B15D-7BF481EC748FQ36925651-96826D2D-3217-4FB0-B18A-D21BD526BC78Q37002789-ED6B6609-D700-4545-8342-C7F80B22B676Q37071539-B5A7FAD1-D4C5-41E2-A266-A3C2F8B2E5EEQ37092527-6D598047-F9C0-4084-9F5D-2B5F3D9721F1Q37299619-8581576F-1113-4927-8D7C-A4CFC4FDCD94Q37309837-84B15DCA-D27A-4C2A-B12A-309AC549862FQ37309838-AA39F829-A34F-4787-B2E7-D3668BAAEB4BQ37362778-EA08E345-13AA-4FA9-BA8B-9F5523942651Q37376117-C176C19E-36FB-4EB0-9FB6-7F4C190DB99B
P2860
Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Clinical and pathological feat ...... 3Thr alpha-synuclein mutation.
@en
Clinical and pathological feat ...... 3Thr alpha-synuclein mutation.
@nl
type
label
Clinical and pathological feat ...... 3Thr alpha-synuclein mutation.
@en
Clinical and pathological feat ...... 3Thr alpha-synuclein mutation.
@nl
prefLabel
Clinical and pathological feat ...... 3Thr alpha-synuclein mutation.
@en
Clinical and pathological feat ...... 3Thr alpha-synuclein mutation.
@nl
P2093
P356
P1433
P1476
Clinical and pathological feat ...... 3Thr alpha-synuclein mutation.
@en
P2093
Cavanagh J
Halliday G
Nicholson GA
P304
P356
10.1002/ANA.67.ABS
P577
2001-03-01T00:00:00Z